巴曲酶治疗不同时间脑梗塞疗效观察

The Observation on Efficacy of Batroxobin in the Treatment of Cerebral Infarction of Different Time

巴曲酶是一种新型的溶栓、改善微循环的治疗剂。观察巴曲酶治疗急性期及恢复期脑梗塞41例，与42例血栓通十脑活素治疗对照，结果显效率和总有效率分别是73．17％和90．21％，对照组分别是16.67％和69.05％，两者显效率有非常显著差异（P＜0.05），总有效率亦有显著差异（P＜0.05）；治疗组中轻型脑梗塞发病3天内疗效最佳。结果显示该药效果明显，安全性高，副作用少，且宜于早期应用。

Batroxobin is a new dissovie-emloli medicine, which can improve microcirculation. 41 patients with cerebral infarction in acute period and eonvalescent period treated were observed. Rate of striking effect and total improvement rate were 73. 17% and 90. 24% respectively. Compared with 42 patients controls treated with XueShuanTong and cerebrolysin, which rate of striking effect and total improvement rate were 16. 67% and 69. 05% respectively, there were marked differences in rate or stricking effect(P<0. 01 ) and in total improvement rate (P<0. 05) between batroxobin group and control group. In batroxobin group, the best efficacy was slight cerebral infarction, which attacked within the early 3 days. The data indicated that effects of this medicine was apparent, safe with little aide-effects. Batroxobin is suitable for early use.